Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04088409) looked at two medicines — baricitinib and adalimumab — in children and young people with a condition causing inflammation inside the eye (uveitis). In the first part of the trial (Part A), 25 participants were assigned to baricitinib and 5 to adalimumab. Of those, 24 and 5 respectively received at least one dose. The trial was primarily measuring how many participants showed a meaningful reduction in eye inflammation by week 24, using a recognised grading system called the SUN criteria, which looks at the level of inflammatory cells in the front part of the eye. The reported data shows that, in the baricitinib group, 33.3% of participants met the definition of a "responder" at week 24 — meaning roughly one in three showed the required reduction in eye inflammation according to the SUN criteria. No equivalent figure was reported for the adalimumab group, which had very small numbers. For all of the secondary outcome measures — including changes in eye inflammation scores, vision test results, and a measure called vitreous haze (cloudiness inside the eye) — the reported data states that results would be provided after the study was completed, meaning those figures were not available in the submitted results. It is also worth noting that the trial had two parts: in Part B, 10 participants from the baricitinib group started but none completed, and no secondary outcome data was reported for this stage either. The reasons participants did not complete each part were not detailed in the submitted results data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 34627340) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of eye inflammation linked to juvenile idiopathic arthritis (JIA-U) or a long-term eye condition called chronic anterior uveitis that tested positive for a certain antibody (ANA), without other body-wide symptoms.
- You currently have active eye inflammation in the front part of your eye, at a certain level of severity, even after being treated with steroid eye drops and a medication called methotrexate (MTX).
- Your body has not responded well enough to methotrexate, or you were not able to tolerate it.
- You have been using steroid eye drops at a steady dose for at least 2 weeks before the start of the study, using no more than 4 drops per day per eye.
- You and any partner who could become pregnant must agree to use 2 reliable forms of contraception throughout the study and for at least 1 week after the last dose of the study medication.
Who may not be able to join:
- You have, or have had, another autoimmune condition (such as Crohn's disease or ulcerative colitis) in addition to JIA.
- You have a medical reason that prevents you from safely taking the medication adalimumab — though there is an exception if you previously did not respond to or could not tolerate certain biological medications, in which case you may still be considered for the trial (confirm with trial site).
- You have had high eye pressure (25 mmHg or above), or needed treatment for eye pressure problems — including extra medication, surgery, or a hospital stay — within 4 weeks before the study starts.
- You have had eye surgery (such as for cataracts, glaucoma, or a procedure inside the eye) within the 3 months before the study screening.
- You currently have, or recently had (within 4 weeks before the study starts), an infection of any kind.
- Your blood test showed a positive result for hepatitis B at the time of screening.
- You have signs of active tuberculosis (TB), or you have latent (inactive) TB that has not been treated.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A: Percentage of Responders for Baricitinib at Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.